Cephalon Challenges Sun's Anti-Epilepsy Generic

Law360, New York (September 22, 2011, 7:22 PM EDT) -- Cephalon Inc. hit Sun Pharmaceutical Industries Inc. with a suit in New Jersey federal court Wednesday alleging its attempts to market a generic version of an anti-epilepsy drug infringed a Cephalon patent.

The plaintiff claims Sun is infringing a patent on its Gabitril tablets by seeking U.S. Food and Drug Administration approval to manufacture generics in the form of 2-milligram and 4-milligram tiagabine hydrochloride tablets.

The patent-in-suit is U.S. Patent Number 5,958,951, which was issued to Novo Nordisk A/S in 1999 and subsequently assigned to Cephalon....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.